Actively Recruiting
Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients: A Prospective Monocentric Study
Led by Centre Hospitalier Universitaire Saint Pierre · Updated on 2025-02-07
150
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Non-alcoholic Fatty Liver Disease (NAFLD) is a condition where fat builds up in the liver of people who drink little or no alcohol. It can range from simple fat accumulation to inflammation and liver cell damage known as non-alcoholic steatohepatitis (NASH). This condition is common, especially in developed countries, and is often linked to metabolic issues like obesity and insulin resistance. Researchers are studying how NAFLD relates to Inflammatory Bowel Disease (IBD), as many IBD patients also develop NAFLD, but the connection and disease behavior are not well understood. Patients with IBD will be observed during both active and remission phases of their intestinal disease. Data such as age, gender, body mass index, alcohol and smoking habits, medical history, IBD type, disease duration, and treatments will be collected. Liver fat and fibrosis will be assessed using transient elastometry (Fibroscan), measuring specific parameters to evaluate liver health. Patients will be followed over time, with repeated assessments when their IBD activity changes. During the study, participants will have clinical evaluations including questionnaires completed by their gastroenterologist, blood tests, and liver stiffness measurements. The main goal is to measure how common NAFLD is in IBD patients and to see how it changes with IBD activity. Additional factors influencing NAFLD will also be studied. The study period lasts up to 12 months, with ongoing monitoring of disease markers and liver condition.
CONDITIONS
Brief Title
Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Inflammatory Bowel Disease based on clinical, endoscopic, and histological criteria according to ECCO guidelines
- Willingness to provide informed consent for participation
- Age 18 years or older
You will not qualify if you...
- Presence of other established liver diseases such as autoimmune hepatitis, primary biliary cholangitis, hemochromatosis, Wilson's disease, or viral hepatitis B or C
- History of hepatocellular carcinoma or liver transplantation
- Excessive alcohol consumption (>3 units/day for women, >5 units/day for men)
- Pregnancy at the time of recruitment
- Inability to perform or missing data from transient elastometry (Fibroscan) measurements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At enrollment
Participants undergo baseline assessment including demographic and clinical data collection, clinical questionnaires, and transient elastometry (Fibroscan) to evaluate liver condition.
1 visit (in-person)
Duration - Up to 12 months
Participants are followed over time with assessments during their usual care. Clinical questionnaires, blood tests, and repeat transient elastometry are performed when intestinal disease activity changes.
Visits occur as needed based on disease activity changes
Trial Site Locations
Total: 1 location
1
CHU Saint Pierre
Brussels, Belgium, 1000
Actively Recruiting
Research Team
J
Jennifer Aoun, Medical Doctor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here